ASX Biotech Stocks In Focus As Invion Targets Eye Disease After Opthea Setback

Highlights

• Invion shares surged after announcing a new wet AMD collaboration with South Korea’s Sangmyung.
• The partnership aims to explore a photodynamic therapy approach for difficult eye diseases.
• Broader biotech activity also included updates from Amplia, Island Pharmaceuticals, Micro-X, and Pacific Edge.

Invion shares gained strong attention after the company announced a new wet AMD collaboration while broader ASX biotech activity accelerated across healthcare stocks.

Invion Ltd (ASX:IVX) attracted strong market attention after unveiling a collaboration targeting wet age-related macular degeneration (wet AMD), a difficult eye disease that recently triggered major setbacks across the biotech sector.

The announcement reignited interest across the broader ASX Biotech Stocks space as healthcare companies continue pursuing specialised therapies linked to oncology, infectious disease, medical imaging, and diagnostics.

Invion enters wet AMD collaboration

Invion announced a collaboration with South Korean ophthalmology specialist Sangmyung to explore a new treatment approach for wet AMD.

The partnership will focus on preclinical proof-of-concept studies using Invion’s Photosoft platform combined with Sangmyung’s eye-drug delivery technology.

The Photosoft platform is based on photodynamic therapy, commonly referred to as PDT, which uses photosensitising compounds activated by light to selectively target diseased cells.

Wet AMD remains one of the leading causes of severe vision loss globally, particularly among older populations.

Wet AMD remains a difficult treatment area

The wet AMD sector has attracted significant research activity in recent years due to the complexity of the disease and the large unmet treatment need.

The condition accounts for a relatively small proportion of AMD cases overall but is responsible for the majority of severe blindness outcomes linked to the disease.

Several biotech companies have previously attempted to develop new wet AMD therapies, with mixed outcomes.

The market opportunity remains significant because a sizeable portion of patients continue showing limited response to existing standard-of-care therapies.

Within the broader ASX 200 healthcare landscape, ophthalmology and specialised treatment platforms remain highly competitive and research-intensive sectors.

Market responds positively to early-stage progress

Invion shares moved sharply higher following the collaboration announcement despite the project remaining in the early preclinical stage.

Biotech stocks often experience significant volatility following announcements tied to partnerships, clinical programs, or early-stage research milestones.

The market reaction highlighted ongoing interest in companies pursuing differentiated treatment technologies across specialised disease categories.

Amplia advances pancreatic cancer study

Elsewhere in the healthcare sector, Amplia Therapeutics Ltd (ASX:ATX) confirmed the launch of a new pancreatic cancer study involving its narmafotinib treatment program.

The company plans to evaluate daily dosing alongside established chemotherapy agents in advanced pancreatic cancer patients.

Pancreatic cancer remains one of the most difficult cancers to treat, making positive efficacy signals particularly important within oncology research.

Amplia also continues preparing for future larger-scale development pathways as it advances clinical-stage programs.

Island Pharmaceuticals targets Marburg virus

Island Pharmaceuticals Ltd (ASX:ILA) also attracted attention after outlining plans for a Marburg virus dose optimisation study.

The company intends to utilise the US FDA’s Animal Rule framework for development of its antiviral candidate Galidesivir.

Marburg belongs to the same virus family as Ebola and remains one of the world’s most dangerous viral haemorrhagic fevers.

Global health security and infectious disease preparedness continue supporting investment interest across specialised antiviral development programs.

Micro-X secures US contract extension

Medical imaging company Micro-X Ltd (ASX:MX1) announced an extension tied to its airport security screening technology program in the United States.

The extension supports additional development work involving baggage self-screening technology and airport checkpoint systems.

Micro-X specialises in cold cathode X-ray technology, which remains an emerging area within advanced imaging systems.

The broader healthcare and medical technology sector continues benefiting from growing demand for imaging, security, and diagnostic innovation.

Pacific Edge progresses reimbursement efforts

Pacific Edge Ltd (ASX:PEB) also gained attention following developments tied to Medicare reimbursement for its bladder cancer diagnostic products in the United States.

The company confirmed progress surrounding draft local coverage determinations involving its Cxbladder diagnostic assays.

Reimbursement decisions remain critically important across the diagnostics sector because they directly influence commercial adoption and healthcare accessibility.

Biotech sector remains highly active

Australia’s biotechnology and healthcare sector continues producing significant research, clinical, and commercial developments across multiple therapeutic areas.

Oncology, diagnostics, infectious disease, ophthalmology, and medical imaging remain among the most closely watched categories within the local biotech landscape.

Companies pursuing differentiated technologies or addressing difficult disease categories often attract heightened market attention due to the potential scale of global healthcare demand.

Clinical development risks remain important

Despite the strong market reactions surrounding several announcements, biotechnology development remains highly complex and uncertain.

Clinical studies, regulatory approvals, reimbursement pathways, and commercial execution all remain critical factors influencing long-term outcomes across the sector.

The recent history of wet AMD research also highlights how difficult certain therapeutic areas can be despite strong scientific interest and substantial market opportunities.

Healthcare innovation continues driving interest

The broader ASX Healthcare Stocks sector continues attracting attention as companies pursue innovation across pharmaceuticals, diagnostics, medical devices, and biotechnology.

Global ageing populations, rising healthcare demand, and advances in medical research continue supporting long-term industry growth themes.